Skip to main content
Fig. 3 | Pediatric Rheumatology

Fig. 3

From: Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis

Fig. 3

Average Weekly Doses of Etanercept Over the First Year of Therapy for All Indications* ETN, etanercept. *All indications refers to patients with a drug history representing juvenile idiopathic arthritis, psoriatic arthritis, or ankylosing spondylitis. Indications were inferred using an algorithm developed by IQVIA, which utilize a patient’s drug history [7, 8, 30]

Back to article page